Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

48.97 +0.62 (+1.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,341,950
Open 48.01
Bid (Size) 48.88 (11)
Ask (Size) 49.01 (27)
Prev. Close 48.35
Today's Range 47.98 - 50.54
52wk Range 17.86 - 58.40
Shares Outstanding 50,086,978
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Akero Therapeutics Stock Rallies To 3-Month High On Buyout Report; Retail Investors Turn Bullish
The company reportedly hired an investment bank to explore a possible sale. 
Via Stocktwits
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga

Performance

YTD
+74.4%
+74.4%
1 Month
+30.0%
+30.0%
3 Month
-3.4%
-3.4%
6 Month
+59.8%
+59.8%
1 Year
+141.9%
+141.9%

More News

Read More
Best Biotech Stocks to Buy in 2025
Via MarketBeat
Topics ETFs Economy Government
Exposures COVID-19 Interest Rates Political
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
This Stock Just Doubled in 1 Day -- Is It Still a Buy?
Via The Motley Fool
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Long-Term Shareholders Have Rights – If You Hold Akero Therapeutics, Inc. (NASDAQ: AKRO); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Mercury Systems, Inc. (NASDAQ: MRCY); or Virtu Financial Inc. (NASDAQ: VIRT), Contact Grabar Law Office
From Grabar Law Office
Via GlobeNewswire
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is
From Grabar Law Office
Via GlobeNewswire
The Stock Market Hates Uncertainty & Loves To Climb A Wall-Of-Worry
Via Talk Markets
Topics ETFs Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Mid-Caps Worth Watching Closely in March
Via MarketBeat
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino’s Pizza Corp. (NASDAQ: DPZ)
From Grabar Law Office
Via GlobeNewswire
Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio?
Via Benzinga
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
From Akero Therapeutics Inc.
Via GlobeNewswire
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Royal Caribbean Cruises Posts Upbeat Earnings, Joins Brighthouse Financial, Invesco, Boeing And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
McDonald's To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Akero Therapeutics Announces Proposed Public Offering of Common Stock
From Akero Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Akero Therapeutics, Inc. - Common Stock publicly traded?
Yes, Akero Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Akero Therapeutics, Inc. - Common Stock trade on?
Akero Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Akero Therapeutics, Inc. - Common Stock?
The ticker symbol for Akero Therapeutics, Inc. - Common Stock is AKRO on the Nasdaq Stock Market
What is the current price of Akero Therapeutics, Inc. - Common Stock?
The current price of Akero Therapeutics, Inc. - Common Stock is 48.97
When was Akero Therapeutics, Inc. - Common Stock last traded?
The last trade of Akero Therapeutics, Inc. - Common Stock was at 05/22/25 04:00 PM ET
What is the market capitalization of Akero Therapeutics, Inc. - Common Stock?
The market capitalization of Akero Therapeutics, Inc. - Common Stock is 2.45B
How many shares of Akero Therapeutics, Inc. - Common Stock are outstanding?
Akero Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.